Question to the Department of Health and Social Care:

To ask Her Majesty's Government what plans they have (1) to review the treatment options for immune-compromised individuals, and (2) to deploy Bebtelovimab as a treatment for such patients.

The Antivirals and Therapeutics Taskforce works with the RAPID C-19 Collaborative to review data from clinical trials for COVID-19 treatments. Bebtelovimab and other monoclonal antibodies are reviewed as part of this process. However, as Bebtelovimab has not received regulatory approval in the United Kingdom, it is not currently being procured for National Health Service patients. Licensing decisions are made by the independent regulator, the Medicines and Healthcare products Regulatory Agency.